Shahzada Khan

Shahzada Khan

Auto-generated profile, based on publicly available information

Shahzada Khan

Virology and Immunology, Gladstone Institutes, San Francisco, CA, 94158, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Molecular Cell
Verified
Journal Article
Closed access
CIChiaki Ito
Chiaki Ito
YSYohei Saito
Yohei Saito
TNTakashi Nozawa
Takashi Nozawa
SFShigemoto Fujii
Shigemoto Fujii
TSTomohiro Sawa
Tomohiro Sawa
HAHirokazu Arimoto
Hirokazu Arimoto

22 February 2018 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
LHLouise E Hogan
Louise E Hogan
JVJoshua Vasquez
Joshua Vasquez
KHKristen S Hobbs
Kristen S Hobbs
EHEmily Hanhauser
Emily Hanhauser
BABrandon Aguilar-Rodriguez
Brandon Aguilar-Rodriguez
THTimothy J Henrich
Timothy J Henrich
HIV-1-infected cells persist indefinitely despite the use of combination antiretroviral therapy (ART), and novel therapeutic strategies to target and purge residual infected cells in individuals on ART are urgently needed. Here, we demonstrate that CD4+ T cell-associated HIV-1 RNA is often highly enriched in cells expressing CD30, and that cells expressing this marker considerably contribute to the total pool of transcriptionally active CD4+ lymphocytes in individuals on suppressive ART. Using in situ RNA hybridization studies, we show co-localization of CD30 with HIV-1 transcriptional activity in gut-associated lymphoid tissues. We also demonstrate that ex vivo treatment with brentuximab vedotin, an antibody-drug conjugate (ADC) that targets CD30, significantly reduces the total amount of HIV-1 DNA in peripheral blood mononuclear cells obtained from infected, ART-suppressed individuals. Finally, we observed that an HIV-1-infected individual, who received repeated brentuximab vedotin infusions for lymphoma, had no detectable virus in peripheral blood mononuclear cells. Overall, CD30 may be a marker of residual, transcriptionally active HIV-1 infected cells in the setting of suppressive ART. Given that CD30 is only expressed on a small number of total mononuclear cells, it is a potential therapeutic target of persistent HIV-1 infection. Previous studies have shown that higher levels of soluble CD30 are associated with HIV-1 disease progression. Many of these studies, however, were performed prior to the implementation of combination ART, and the relationship between surface CD30 expression, soluble CD30 and HIV-1 infection in ART suppressed individuals, or those with viremic control off ART, is not known. We demonstrate that cell-associated HIV-1 RNA is highly enriched in CD4+ T cells expressing CD30, a member of the tumor necrosis factor receptor superfamily. These findings were observed in several HIV-1 infected donor groups, regardless of whether or not the participants were receiving suppressive ART. Furthermore, we demonstrate that ex vivo treatment with brentuximab vedotin, an antibody-drug conjugate that targets CD30, reduces the total amount of HIV-1 DNA in PBMC obtained from infected individuals. Finally, we show through in situ RNA hybridization studies that CD30 and HIV transcriptional activity co-localize in cells from gut biopsies obtained from HIV-1 infected donors. These data suggest that CD30 may be a marker of residual, transcriptionally active HIV-1 infected cells in the setting of suppressive ART.

15 April 2014 in Scientific Reports
Verified
Journal Article
Open access
SKShahzada Khan
Shahzada Khan
HRH. N. Ashiqur Rahman
H. N. Ashiqur Rahman
TOTatsuya Okamoto
Tatsuya Okamoto
TMTetsuro Matsunaga
Tetsuro Matsunaga
YFYukio Fujiwara
Yukio Fujiwara
TATakaaki Akaike
Takaaki Akaike
Helicobacter cinaedi is the most common enterohepatic Helicobacter species that causes bacteremia in humans, but its pathogenicity is unclear. Here, we investigated the possible association of H. cinaedi with atherosclerosis in vivo and in vitro. We found that H. cinaedi infection significantly enhanced atherosclerosis in hyperlipidaemic mice. Aortic root lesions in infected mice showed increased accumulation of neutrophils and F4/80+ foam cells, which was due, at least partly, to bacteria-mediated increased expression of proinflammatory genes. Although infection was asymptomatic, detection of cytolethal distending toxin RNA of H. cinaedi indicated aorta infection. H. cinaedi infection altered expression of cholesterol receptors and transporters in cultured macrophages and caused foam cell formation. Also, infection induced differentiation of THP-1 monocytes. These data provide the first evidence of a pathogenic role of H. cinaedi in atherosclerosis in experimental models, thereby justifying additional investigations of the possible role of enterohepatic Helicobacter spp. in atherosclerosis and cardiovascular disease.

1 November 2018 in Cell Chemical Biology
Verified
Journal Article
Closed access
SKShahzada Khan
Shahzada Khan
SFShigemoto Fujii
Shigemoto Fujii
TMTetsuro Matsunaga
Tetsuro Matsunaga
ANAkira Nishimura
Akira Nishimura
KOKatsuhiko Ono
Katsuhiko Ono
TATakaaki Akaike
Takaaki Akaike

16 November 2016 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SKShahzada Khan
Shahzada Khan
EWErik M. Woodruff
Erik M. Woodruff
MTMartin Trapecar
Martin Trapecar
KFKrystal A. Fontaine
Krystal A. Fontaine
AEAshley Ezaki
Ashley Ezaki
SSShomyseh Sanjabi
Shomyseh Sanjabi
Understanding the host immune response to vaginal exposure to RNA viruses is required to combat sexual transmission of this class of pathogens. In this study, using lymphocytic choriomeningitis virus (LCMV) and Zika virus (ZIKV) in wild-type mice, we show that these viruses replicate in the vaginal mucosa with minimal induction of antiviral interferon and inflammatory response, causing dampened innate-mediated control of viral replication and a failure to mature local antigen-presenting cells (APCs). Enhancement of innate-mediated inflammation in the vaginal mucosa rescues this phenotype and completely inhibits ZIKV replication. To gain a better understanding of how this dampened innate immune activation in the lower female reproductive tract may also affect adaptive immunity, we modeled CD8 T cell responses using vaginal LCMV infection. We show that the lack of APC maturation in the vaginal mucosa leads to a delay in CD8 T cell activation in the draining lymph node and hinders the timely appearance of effector CD8 T cells in vaginal mucosa, thus further delaying viral control in this tissue. Our study demonstrates that vaginal tissue is exceptionally vulnerable to infection by RNA viruses and provides a conceptual framework for the male to female sexual transmission observed during ZIKV infection.

1 November 2017 in AIDS Research and Human Retroviruses
Verified
Journal Article
Open access
SKShahzada Khan
Shahzada Khan
STSUSHAMA TELWATTE
SUSHAMA TELWATTE
MTMartin Trapecar
Martin Trapecar
SYSteven Yukl
Steven Yukl
SSShomyseh Sanjabi
Shomyseh Sanjabi
The single greatest challenge to an HIV cure is the persistence of latently infected cells containing inducible, replication-competent proviral genomes, which constitute only a small fraction of total or infected cells in the body. Although resting CD4 + T cells in the blood are a well-known source of viral rebound, more than 90% of the body's lymphocytes reside elsewhere. Many are in gut tissue, where HIV DNA levels per million CD4 + T cells are considerably higher than in the blood. Despite the significant contribution of gut tissue to viral replication and persistence, little is known about the cell types that support persistence of HIV in the gut; importantly, T cells in the gut have phenotypic, functional, and survival properties that are distinct from T cells in other tissues. The mechanisms by which latency is established and maintained will likely depend on the location and cytokine milieu surrounding the latently infected cells in each compartment. Therefore, successful HIV cure strategies require identification and characterization of the exact cell types that support viral persistence, particularly in the gut. In this review, we describe the seeding of the latent HIV reservoir in the gut mucosa; highlight the evidence for compartmentalization and depletion of T cells; summarize the immunologic consequences of HIV infection within the gut milieu; propose how the damaged gut environment may promote the latent HIV reservoir; and explore several immune cell targets in the gut and their place on the path toward HIV cure.